Recombinant Human CD22 Protein (Asp20-Arg687), C-hFc and Avi-tagged, Biotinylated
Product Description
Cat
IMP-10270
Official Symbol
CD22
Product Overview
Biotinylated recombinant human Siglec-2/CD22 protein (Asp20-Arg687) with a Human IgG1 (Pro100-Lys330) Fc tag and Avi-tag at C-terminus was expressed in Chinese Hamster Ovary cell line.
Description
Predicted to enable CD4 receptor binding activity; protein phosphatase binding activity; and sialic acid binding activity. Involved in B cell activation; negative regulation of B cell receptor signaling pathway; and regulation of endocytosis. Located in early endosome and recycling endosome.
Expression System
CHO
Species
Human
Tag
C-hFc and Avi
Predicted N Terminal
Asp20
Form
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Conjugate
Biotinylated
Molecular Mass
Predicted Molecular Mass: 104 kDa
SDS-PAGE: 120-140 kDa, under reducing conditions.
Protein length
Asp20-Arg687
Bio-activity
Measured by the ability of the immobilized protein to support the adhesion of human red blood cells. The ED50 for this effect is 0.1-0.9 μg/mL. Measured by its binding ability in a functional ELISA. When Human Siglec-2/CD22 (Epratuzumab) Antibody is immobilized at 0.2 μg/mL (100 μL/well), Biotinylated Recombinant Human Siglec-2/CD22 Fc Chimera Avi-tag binds with an ED50 of 1.5-18 ng/mL.
Endotoxin
<0.10 EU/μg of the protein by the LAL method.
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie Blue Staining.
Notes
Disulfide-linked homodimer, biotinylated via Avi-tag
Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 centigrade as supplied.
1 month, 2 to 8 centigrade under sterile conditions after reconstitution.
3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitution
Reconstitute at 500 μg/mL in PBS.
SDS-PAGE
SDS-PAGE

Bioactivity-ELISA 1
Bioactivity

Measured by the ability of the immobilized protein to support the adhesion of human red blood cells. The ED50 for this effect is 0.1-0.9 μg/mL. Measured by its binding ability in a functional ELISA. When Human Siglec-2/CD22 (Epratuzumab) Antibody is immobilized at 0.2 μg/mL (100 μL/well), Biotinylated Recombinant Human Siglec-2/CD22 Fc Chimera Avi-tag binds with an ED50 of 1.5-18 ng/mL.

Data Sheet MSDS
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Online Inquiry
Contact Info